Antibodies News and Research RSS Feed - Antibodies News and Research

Low blood level of 4 proteins can help diabetics protect against immune attack

Low blood level of 4 proteins can help diabetics protect against immune attack

Patients with type 1 diabetes have significantly lower blood levels of four proteins that help protect their tissue from attack by their immune system, scientists report. [More]
Two-step regimen of experimental MERS vaccines show promise in mice

Two-step regimen of experimental MERS vaccines show promise in mice

A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines. Vaccinated mice produced broadly neutralizing antibodies against multiple strains of the MERS coronavirus (MERS-CoV), while vaccinated macaques were protected from severe lung damage when later exposed to MERS-CoV. [More]
AMSBIO launches CellMax™ Cell Pellet Slides

AMSBIO launches CellMax™ Cell Pellet Slides

AMSBIO announces the launch of CellMax™ - a new range of high quality, consistent and affordable cell line FFPE slides. [More]
Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

Regeneron Pharmaceuticals, Inc. and Sanofi have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology. [More]
Necrotising autoimmune myopathy requires early, aggressive treatment

Necrotising autoimmune myopathy requires early, aggressive treatment

Researchers call for the prompt recognition of necrotising autoimmune myopathy and aggressive early treatment with a combination of intravenous immune globulin, corticosteroids and a steroid-sparing agent for 3 months. [More]
New paper describes positive effects of CRAC channel inhibitors in animal models of acute pancreatitis

New paper describes positive effects of CRAC channel inhibitors in animal models of acute pancreatitis

Researchers from CalciMedica, Inc. and the University of Liverpool today announced the publication of a paper describing positive effects of calcium release-activated calcium (CRAC) channel inhibitors in animal models of acute pancreatitis. The paper, titled "Inhibitors of ORAI1 prevent cytosolic calcium-associated injury of human pancreatic acinar cells and acute pancreatitis in 3 mouse models" appears in the August edition of the journal Gastroenterology. [More]
TSRI awarded two grants to support development of effective vaccine against HIV/AIDS

TSRI awarded two grants to support development of effective vaccine against HIV/AIDS

The Scripps Research Institute has been awarded two grants from the Bill & Melinda Gates Foundation totaling more than $4.5 million to fund efforts to develop a vaccine against HIV/AIDS. [More]
New Histone Antibody Specificity Database allows scientists to find right antibodies for biomedical research

New Histone Antibody Specificity Database allows scientists to find right antibodies for biomedical research

For years, a crisis has been brewing in molecular biology. The problem is that antibodies--research tools used to identify key proteins at work in a cell--aren't always what they seem. Unreliable antibodies have led to numerous instances of false findings, failed experiments, and wasted money and samples. [More]
Omeros' OMS721 granted FDA Fast Track designation for treatment of atypical hemolytic uremic syndrome

Omeros' OMS721 granted FDA Fast Track designation for treatment of atypical hemolytic uremic syndrome

Omeros Corporation today announced that the U.S. Food and Drug Administration granted Fast Track designation to OMS721 for the treatment of patients with atypical hemolytic uremic syndrome (aHUS). OMS721 is the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system. [More]
Study points to potential treatment for thrombotic thrombocytopenic purpura

Study points to potential treatment for thrombotic thrombocytopenic purpura

A rare autoimmune disease creates sudden pain in the abdomen or the head, sending a patient to the emergency room with a potentially fatal condition. The pain comes from a multitude of blockages of tiny blood vessels, formed after the patient's own immune system somehow inhibits an enzyme that is vital to control clotting. [More]
New technique holds promise for improving glycoprotein-based pharmaceuticals

New technique holds promise for improving glycoprotein-based pharmaceuticals

Researchers from the University of Copenhagen have discovered a way of improving biotech drugs. Better, cheaper and more effective drugs to combat cancer, arthritis and many other disorders. [More]
New drug cures malaria in mice

New drug cures malaria in mice

A new drug acts as a roadblock for malaria, curing mice of established infection, according to a study in The Journal of Experimental Medicine. Treatment was not associated with obvious side effects, suggesting that the drug may also be safe and effective in humans. [More]
New monoclonal antibodies may provide blueprint for effective Alzheimer's disease treatments

New monoclonal antibodies may provide blueprint for effective Alzheimer's disease treatments

Scientists at NYU Langone Medical Center's Center for Cognitive Neurology have evidence that monoclonal antibodies they developed may provide the blueprint for effective treatments for Alzheimer's disease and other neurodegenerative diseases, such as Parkinson's disease. [More]
Inova Diagnostics announces FDA clearance for QUANTA Flash assays, QUANTA Flash Beta-2GP1 Domain1

Inova Diagnostics announces FDA clearance for QUANTA Flash assays, QUANTA Flash Beta-2GP1 Domain1

Inova Diagnostics, a worldwide leader in autoimmune diagnostic reagents and systems for the clinical laboratory, announced today that it has received 510(k) clearance by the U.S. Food and Drug Administration on key QUANTA Flash assays for use with Inova Diagnostics' BIO-FLASH chemiluminescent analyzer for autoimmune testing. [More]
New study may help identify novel ways to treat immune thrombocytopenia

New study may help identify novel ways to treat immune thrombocytopenia

Immune thrombocytopenia, or ITP, is an autoimmune disease whereby the immune system sends antibodies to attack and destroy the body's platelets--blood cells responsible for controlling bleeding. [More]
C2N-8E12 (ABBV-8E12) gets orphan drug designation from FDA for PSP treatment

C2N-8E12 (ABBV-8E12) gets orphan drug designation from FDA for PSP treatment

C2N Diagnostics and AbbVie today announced that the U.S. Food and Drug Administration has granted their investigational recombinant humanized anti-tau antibody, C2N-8E12 (ABBV-8E12), an orphan drug designation for the treatment of progressive supranuclear palsy (PSP). [More]
AESKU.DIAGNOSTICS offers new early prognostic marker for RA

AESKU.DIAGNOSTICS offers new early prognostic marker for RA

Activity and outcome scores like DAS, DAS28, SDAI or CDAI, Larsen Score, etc. are commonly used but are time consuming and not practical in the early phase of rheumatoid arthritis (RA). [More]
Protagonist Therapeutics closes $40 million Series C financing

Protagonist Therapeutics closes $40 million Series C financing

Protagonist Therapeutics, Inc., a company developing novel, orally stable peptide therapeutics for gastrointestinal diseases and disorders, today announced the closing of a $40 million Series C financing. [More]
Immunocore completes $320 million (£205 million) private financing round

Immunocore completes $320 million (£205 million) private financing round

Immunocore Limited, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune disease, today announced the completion of a US $320 million (GBP £205 million) private financing round. [More]
New research offers potential for early intervention to prevent neurodegenerative diseases

New research offers potential for early intervention to prevent neurodegenerative diseases

New research led by investigators at Beth Israel Deaconess Medical Center provides the first direct evidence linking traumatic brain injury to Alzheimer's disease and chronic traumatic encephalopathy (CTE) -- and offers the potential for early intervention to prevent the development of these debilitating neurodegenerative diseases. [More]
Advertisement
Advertisement